200,000+ products from a single source!
sales@angenechem.com
144675-97-8 | Benz[g]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-2-butenedioate (1:2)
CAS No: 144675-97-8 Catalog No: AG001JYV MDL No:MFCD00920108
Product Description
Catalog Number:
AG001JYV
Chemical Name:
Benz[g]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-2-butenedioate (1:2)
CAS Number:
144675-97-8
Molecular Formula:
C25H27N5O10
Molecular Weight:
557.5094
MDL Number:
MFCD00920108
IUPAC Name:
6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione;(Z)-but-2-enedioic acid
InChI:
InChI=1S/C17H19N5O2.2C4H4O4/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24;2*5-3(6)1-2-4(7)8/h1-3,6,9,21-22H,4-5,7-8,18-19H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
InChI Key:
SVAGFBGXEWPNJC-SPIKMXEPSA-N
SMILES:
OC(=O)/C=C\C(=O)O.OC(=O)/C=C\C(=O)O.NCCNc1ccc(c2c1C(=O)c1cnccc1C2=O)NCCN
UNII:
P0R64C4CR9
Properties
Complexity:
591
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
3
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
2
Exact Mass:
557.176g/mol
Formal Charge:
0
Heavy Atom Count:
40
Hydrogen Bond Acceptor Count:
15
Hydrogen Bond Donor Count:
8
Isotope Atom Count:
0
Molecular Weight:
557.516g/mol
Monoisotopic Mass:
557.176g/mol
Rotatable Bond Count:
10
Topological Polar Surface Area:
272A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis. | Journal of neuroimmunology 20130515 |
| The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. | The Journal of pharmacology and experimental therapeutics 20130201 |
| Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. | The Lancet. Oncology 20120701 |
| Pixantrone: a new agent for relapsed aggressive lymphomas. | The Lancet. Oncology 20120701 |
| Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. | Cancer 20111115 |
| Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. | Expert opinion on drug metabolism & toxicology 20111101 |
| Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. | Leukemia & lymphoma 20110401 |
| DNA binding by pixantrone. | Organic & biomolecular chemistry 20101207 |
| New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. | Journal of medicinal chemistry 20101014 |
| Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. | Expert opinion on pharmacotherapy 20100801 |
| Lymphoma researchers in search of molecular targets. | Journal of the National Cancer Institute 20100721 |
| Pixantrone maleate for non-Hodgkin's lymphoma. | Drugs of today (Barcelona, Spain : 1998) 20091101 |
| Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas. | Future oncology (London, England) 20090501 |
| CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. | Electrophoresis 20090401 |
| Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. | Molecular pharmacology 20080701 |
| Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. | Journal of immunology (Baltimore, Md. : 1950) 20080215 |
| Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. | Expert opinion on investigational drugs 20071001 |
| Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. | Investigational new drugs 20070601 |
| Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. | Nucleic acids research 20070601 |
| A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. | Leukemia & lymphoma 20070201 |
| EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. | Clinical lymphoma & myeloma 20060901 |
| Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. | Journal of neuroimmunology 20051101 |
| The role of pixantrone in the treatment of non-Hodgkin's lymphoma. | Expert opinion on investigational drugs 20050801 |
| Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. | Journal of the neurological sciences 20040815 |
| Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. | Journal of neuroimmunology 20040601 |
| A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. | Expert opinion on pharmacotherapy 20040401 |
| Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. | Haematologica 20030801 |
| Pixantrone (Novuspharma). | IDrugs : the investigational drugs journal 20030501 |
| Solid-state characterization of a novel chemotherapeutic drug. | Journal of pharmaceutical sciences 20030301 |
| Characterization of anthracenediones and their photoaffinity analogs. | Biochemical pharmacology 20020315 |
| Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20010501 |
| A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010101 |
| Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. | Tumori 20010101 |
| Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. | Molecular pharmacology 19950701 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.